Compare MMC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMC | REGN |
|---|---|---|
| Founded | 1871 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9B | 73.9B |
| IPO Year | N/A | 1991 |
| Metric | MMC | REGN |
|---|---|---|
| Price | $181.80 | $774.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 23 |
| Target Price | $215.31 | ★ $795.74 |
| AVG Volume (30 Days) | ★ 2.5M | 855.4K |
| Earning Date | 01-29-2026 | 02-03-2026 |
| Dividend Yield | ★ 1.94% | 0.46% |
| EPS Growth | 2.86 | ★ 2.88 |
| EPS | 8.34 | ★ 41.59 |
| Revenue | ★ $26,453,000,000.00 | $14,247,800,000.00 |
| Revenue This Year | $11.27 | $1.99 |
| Revenue Next Year | $5.00 | $6.68 |
| P/E Ratio | $22.25 | ★ $18.56 |
| Revenue Growth | ★ 10.47 | 2.89 |
| 52 Week Low | $174.18 | $476.49 |
| 52 Week High | $248.00 | $792.77 |
| Indicator | MMC | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 61.40 |
| Support Level | $183.92 | $775.00 |
| Resistance Level | $188.50 | $792.77 |
| Average True Range (ATR) | 2.14 | 13.49 |
| MACD | -0.10 | -1.42 |
| Stochastic Oscillator | 3.50 | 69.19 |
Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).